Top Page
Salarius Pharmaceuticals
(NASDAQ:SLRX)
Salarius Pharmaceuticals (SLRX) vs. SPDR S&P 500 ETF (SPY)
Salarius Pharmaceuticals Business Overview & Revenue Model
Salarius Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.23M |
| Gross Profit | -1.11K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23M |
| EBITDA | -5.04M | -5.73M | -12.88M | -22.97M | -12.79M | -7.59M |
| Net Income | -5.00M | -5.58M | -12.54M | -31.61M | -12.77M | -7.35M |
Balance Sheet | ||||||
| Total Assets | 6.10M | 3.02M | 6.59M | 14.65M | 40.83M | 24.93M |
| Cash, Cash Equivalents and Short-Term Investments | 4.81M | 2.43M | 5.90M | 12.11M | 29.21M | 11.12M |
| Total Debt | 0.00 | 221.87K | 289.64K | 0.00 | 0.00 | 477.03K |
| Total Liabilities | 1.85M | 1.51M | 1.30M | 4.27M | 2.11M | 2.77M |
| Stockholders Equity | 4.25M | 1.51M | 5.29M | 10.38M | 38.72M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.43M | -4.53M | -12.85M | -19.10M | -10.20M | -10.31M |
| Operating Cash Flow | -4.43M | -4.53M | -12.85M | -17.60M | -10.20M | -10.31M |
| Investing Cash Flow | -200.00K | 0.00 | 0.00 | -1.50M | 0.00 | -2.60K |
| Financing Cash Flow | 6.16M | 1.06M | 6.64M | 1.99M | 28.30M | 17.69M |
Salarius Pharmaceuticals Technical Analysis
Salarius Pharmaceuticals Risk Analysis
Salarius Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $3.42M | -0.01 | -139.55% | ― | ― | 68.08% | |
41 Neutral | $1.56M | -0.04 | -60.37% | ― | -100.00% | 86.75% | |
39 Underperform | $640.51K | -0.06 | ― | ― | 178.82% | -4121.10% | |
33 Underperform | $2.58M | >-0.01 | -263.57% | ― | -34.58% | 96.41% | |
29 Underperform | $3.64M | -0.05 | -168.95% | ― | ― | 90.27% |
Salarius Pharmaceuticals Corporate Events
On December 31, 2025, Salarius Pharmaceuticals reconvened its 2025 Annual Meeting of Stockholders, originally held on December 19, 2025, with 39.7% of the 1,051,782 outstanding common shares represented, constituting a quorum. At the meeting, shareholders re-elected two Class I directors to serve until the 2028 annual meeting, approved on a non-binding basis the compensation of the company’s named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, collectively signaling continued shareholder support for the company’s current leadership, governance practices and financial oversight arrangements.
The most recent analyst rating on (SLRX) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Salarius Pharmaceuticals stock, see the SLRX Stock Forecast page.
On December 31, 2025, Salarius Pharmaceuticals, Inc. disclosed that it had received notice from Nasdaq that the company was no longer in compliance with the exchange’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive business days. Because Salarius conducted a reverse stock split within the prior year and remains under a Mandatory Panel Monitor, it is not eligible for the standard 180-day grace period to cure the deficiency, and, absent an appeal by January 7, 2026, its stock is scheduled for suspension and delisting from The Nasdaq Capital Market effective January 9, 2026, followed by deregistration from Nasdaq. The company said it intends to appeal the delisting determination to a Nasdaq Hearings Panel, which would temporarily stay the suspension and delisting process while Salarius presents a plan to regain compliance, although there is no assurance that the panel will rule in favor of maintaining the listing, leaving shareholders exposed to the risk of the stock moving to a less liquid trading venue.
The most recent analyst rating on (SLRX) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Salarius Pharmaceuticals stock, see the SLRX Stock Forecast page.
On December 19, 2025, Salarius Pharmaceuticals convened its 2025 annual meeting of stockholders but was forced to adjourn without conducting business after failing to reach the required 34% quorum, with only about 30% of eligible common shares represented in person or by proxy. The company set December 31, 2025, as the date to reconvene the virtual annual meeting, keeping the October 24, 2025 record date and the existing slate of proposals unchanged, and emphasized the need for additional shareholder participation by encouraging investors of record to submit or maintain their proxies so that key corporate matters can proceed, a step that underscores governance and voting-engagement challenges at the small-cap drug developer.
On November 18, 2025, Salarius Pharmaceuticals entered into employment agreements with Frederick E. Pierce, Dr. Barbara Hibner, and Peter Marschel to serve as Chief Executive Officer, Chief Scientific Officer, and Chief Business Officer, respectively. These agreements outline compensation, benefits, and conditions for termination, including severance pay and benefits under certain circumstances, reflecting strategic leadership appointments aimed at strengthening the company’s executive team.
On November 11, 2025, Salarius Pharmaceuticals announced an underwritten public offering of approximately $7 million, involving common stock and various warrants, with Ladenburg Thalmann & Co. Inc. as the sole underwriter. The offering closed on November 12, 2025, raising net proceeds of around $6.3 million, which will be used to advance clinical development, pay off Decoy Therapeutics’ promissory notes, and for general corporate purposes. Concurrently, Salarius completed a merger with Decoy Therapeutics, making it a wholly-owned subsidiary, and appointed new executives, including Frederick E. Pierce as CEO. This strategic move aims to strengthen Salarius’ market position and expand its research capabilities.
On October 21, 2025, Salarius Pharmaceuticals‘ Board of Directors approved a transaction bonus for Mark J. Rosenblum, the Acting CEO and CFO, contingent on the completion of a merger agreement with Decoy Therapeutics. The bonus of $225,000 will be paid following the closing of the merger, provided Mr. Rosenblum remains employed through the closing date.
On October 10, 2025, Salarius Pharmaceuticals regained compliance with Nasdaq’s Equity Standard, a crucial step in its planned merger with Decoy Therapeutics. The merger aims to leverage Decoy’s peptide conjugate therapeutics and Salarius’ assets to target unmet needs in respiratory diseases and GI oncology. The combined company will be led by Decoy’s leadership team and expects to advance its lead asset to an IND application with the FDA within the next year.
Salarius Pharmaceuticals has taken steps to regain compliance with Nasdaq’s equity standard by issuing and selling shares to raise its stockholders’ equity above the required $2.5 million threshold. The company is awaiting Nasdaq’s confirmation of compliance, and while its financial closing procedures for the quarter ended September 30, 2025, are incomplete, it anticipates that its upcoming quarterly report will reflect the necessary equity level.